Letter to the editor
Score to Assess the Risk of Pneumonia in Coronavirus Disease-19
Sora Yasri1
*
Viroj Wiwanitkit2
1Private Academic Consultant, Bangkok,
Thailand
2Honoray Professor, Dr DY Patil University,
Pune, India
Dear Editor,
We would like to share ideas on the publication, “Development of Simple and Sensitive
Score to Assess the Risk of Pneumonia in Coronavirus disease (COVID-19) Patients”1. Hormanstorfer et al. concluded that “This
sensible score may improve the risk stratification of COVID-19 patients in the
pre-hospital setting”1. Indeed, the
attempt to develop a new scoring system or model for predicting COVID-19 infection or
its severity is interesting. The important point is the requirement for further
validation test on the new system internationally. We would like to draw attention to a
possible underlying confounding factor that can result in decreasing ability of risk
assessment of the new system. In a setting where there is a high rate of underlying
chest disease, such as Asian countries, there is an elevated rate of patients with
silent underlying chest disease. For example, a COVID-19 infection might simultaneously
occur with pulmonary tuberculosis2. The new score
system might not be applicable in those cases.
REFERENCES
1. Hormanstorfer M, Ragusa MA, Poggio L, Moreira-Facundo J,
Orellana-Villa Z, Bobrowski FA, et al. Development of simple and sensitive score
to assess the risk of pneumonia in COVID-19 patients. Rev Invest Clin. 2020;73
[Epub ahead of print].
[ Links ]
2. Yasri S, Wiwanitkit V. Tuberculosis and novel Wuhan Coronavirus
infection:pathological interrelationship. Indian J Tuberc.
2020;67:264.
[ Links ]
Dear Editor,
We have read and appreciate the comments made by Yasri and Wiwanitkit on our article,
“Development of Simple and Sensitive Score to Assess the Risk of Pneumonia in
Coronavirus disease (COVID-19) Patients”1. We
agree that patients with an underlying lung disease (e.g., tuberculosis) may have
respiratory symptoms that do not belong to COVID-19, leading to unnecessary chest images
when applying the score. Regarding this comment, we believe it is important to mention
that the score was developed in Argentina, a country also with a high prevalence of
underlying silent chest disease, and thus, this population is not under-represented in
our cohort. We also believe that the realization of chest images in those patients could
help to differentiate COVID-19 from other diseases. For example, the high-resolution CT
pattern of COVID-19 is relatively specific (peripheric subpleural ground glass
opacities) and distinguishable from COPD or tuberculosis. Consequently, the risk of
misdiagnosis is, in our opinion, reasonably low. However, we agree that the existence of
a previously undiagnosed respiratory disease represents a clinical scenario in which our
score can fail, and thus could be considered a weakness of the clinical prediction
rule.
Copyright: © 2021 Revista de Investigación
Clínica.